In silico frameworks for systematic pre-clinical screening of potential anti-leukemia therapeutics

References

• Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012 Jul 20;150(2):264–278.
   PubMed Web of Science ®Google Scholar
• Khwaja A, Bjorkholm M, Gale RE, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010. DOI:10.1038/nrdp.2016.10.
   PubMed Web of Science ®Google Scholar
• Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008 Feb 22;132(4):631–644.
   PubMed Web of Science ®Google Scholar
• Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer. 2005 Apr;5(4):311–321. DOI:10.1038/nrc1592.
   PubMed Web of Science ®Google Scholar
• Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011 Sep;17(9):1086–1093. DOI:10.1038/nm.2415.
   PubMed Web of Science ®Google Scholar
• Varn FS, Andrews EH, Cheng C. Systematic analysis of hematopoietic gene expression profiles for prognostic prediction in acute myeloid leukemia. Sci Rep. 2015;5:16987. DOI:10.1038/srep16987.
   PubMed Web of Science ®Google Scholar
• Howlader NNA, Krapcho M, Miller D, editors., et al., SEER Cancer statistics review. 1975–2013. Bethesda (MD): National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/ based on November 2015 SEER data submission, posted to the SEER web site.
   Google Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015 Sep 17;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015 May;90(5):446–460. DOI:10.1002/ajh.23979.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood. 2015 Jul 23;126(4):471–477.
   PubMed Web of Science ®Google Scholar
• Jin G, Wong ST. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today. 2014 May;19(5):637–644. DOI:10.1016/j.drudis.2013.11.005.
   PubMed Web of Science ®Google Scholar
• Kitchen DB, Decornez H, Furr JR, et al. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004 Nov;3(11):935–949. DOI:10.1038/nrd1549.
   PubMed Web of Science ®Google Scholar
• Meng XY, Zhang HX, Mezei M, et al. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011 Jun;7(2):146–157.
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000 Jan 1;28(1):235–242.
   PubMed Web of Science ®Google Scholar
• Guha R, Nguyen DT, Southall N, et al. Dealing with the data deluge: handling the multitude of chemical biology data sources. Curr Protoc Chem Biol. 2012 Sep;4:193–209. DOI:10.1002/9780470559277.ch110262.
   PubMedGoogle Scholar
• Banavath HN, Sharma OP, Kumar MS, et al. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. Sci Rep. 2014;4:6948. DOI:10.1038/srep06948.
   PubMed Web of Science ®Google Scholar
• Von Grotthuss M, Koczyk G, Pas J, et al. Ligand.Info small-molecule Meta-Database. Comb Chem High Throughput Screen. 2004 Dec;7(8):757–761.
   PubMed Web of Science ®Google Scholar
• Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014 Jan;42(Database issue):D1091–D1097. DOI:10.1093/nar/gkt1068.
   PubMed Web of Science ®Google Scholar
• Kim S, Thiessen PA, Bolton EE, et al. PubChem Substance and Compound databases. Nucleic Acids Res. 2016 Jan 4;44(D1):D1202–D12013.
   PubMed Web of Science ®Google Scholar
• Cavasotto CN, Phatak SS. Homology modeling in drug discovery: current trends and applications. Drug Discov Today. 2009 Jul;14(13–14):676–683. DOI:10.1016/j.drudis.2009.04.006.
   PubMed Web of Science ®Google Scholar
• Mishra RK, Wei C, Hresko RC, et al. In silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective inhibitors for cancer therapy. J Biol Chem. 2015 Jun 5;290(23):14441–14453. DOI:10.1074/jbc.M114.628826
   PubMed Web of Science ®Google Scholar
• Irwin JJ, Sterling T, Mysinger MM, et al. ZINC: a free tool to discover chemistry for biology. J Chem Inf Model. 2012 Jul 23;52(7):1757–1768.
   PubMed Web of Science ®Google Scholar
• Liao Z, Gu L, Vergalli J, et al. Structure-based screen identifies a potent small molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukemia. Mol Cancer Ther. 2015 Aug;14(8):1777–1793. DOI:10.1158/1535-7163.MCT-14-0883.
   PubMed Web of Science ®Google Scholar
• Monga M, Sausville EA. Developmental therapeutics program at the NCI: molecular target and drug discovery process. Leukemia. 2002 Apr;16(4):520–526. DOI:10.1038/sj.leu.2402464.
   PubMed Web of Science ®Google Scholar
• ChemNavigator. Available from: http://www.chemnavigator.com/.
   Google Scholar
• Ke YY, Singh VK, Coumar MS, et al. Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification. Sci Rep. 2015;5:11702. DOI:10.1038/srep11702.
   PubMed Web of Science ®Google Scholar
• Chen S, Li L, Chen Y, et al. Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through structure-based virtual screening and biological assays. J Chem Inf Model. 2016 Mar 28;56(3):527–534.
   PubMed Web of Science ®Google Scholar
• Kumar H, Raj U, Srivastava S, et al. Identification of dual natural inhibitors for chronic myeloid leukemia by virtual screening, molecular dynamics simulation and ADMET analysis. Interdiscip Sci. 2015 Aug 22;8(3):241–252.
   Web of Science ®Google Scholar
• Acharya C, Coop A, Polli JE, et al. Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des. 2011 Mar;7(1):10–22.
   PubMed Web of Science ®Google Scholar
• Arthur DE, Uzairu A, Mamza P, et al. Quantitative structure–activity relationship study on potent anticancer compounds against MOLT-4 and P388 leukemia cell lines. J Adv Res. 2016;7(5):823–837. DOI:10.1016/j.jare.2016.03.010.
   Web of Science ®Google Scholar
• Katritzky AR, Girgis AS, Slavov S, et al. QSAR modeling, synthesis and bioassay of diverse leukemia RPMI-8226 cell line active agents. Eur J Med Chem. 2010 Nov;45(11):5183–5199. DOI:10.1016/j.ejmech.2010.08.033.
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006 Sep 29;313(5795):1929–1935. DOI:10.1126/science.1132939.
   PubMed Web of Science ®Google Scholar
• Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013 Jan;41(Database issue):D955–D961. DOI:10.1093/nar/gks1111.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Cheng C, Yan X, Sun F, et al. Inferring activity changes of transcription factors by binding association with sorted expression profiles. BMC Bioinformatics. 2007;8:452. DOI:10.1186/1471-2105-8-452.
   PubMed Web of Science ®Google Scholar
• Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010 Nov;11(11):1096–1106. DOI:10.1016/S1470-2045(10)70114-5.
   PubMed Web of Science ®Google Scholar
• Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006 Oct;10(4):331–342. DOI:10.1016/j.ccr.2006.09.006.
   PubMed Web of Science ®Google Scholar
• Hassane DC, Guzman ML, Corbett C, et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood. 2008 Jun 15;111(12):5654–5662. DOI:10.1182/blood-2007-11-126003.
   PubMed Web of Science ®Google Scholar
• Hassane DC, Sen S, Minhajuddin M, et al. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood. 2010 Dec 23;116(26):5983–5990.
   PubMed Web of Science ®Google Scholar
• Marstrand TT, Borup R, Willer A, et al. A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. Leukemia. 2010 Jul;24(7):1265–1275. DOI:10.1038/leu.2010.95.
   PubMed Web of Science ®Google Scholar
• Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001 Oct 29;20(49):7140–7145.
   PubMed Web of Science ®Google Scholar
• Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988 Aug;72(2):567–572.
   PubMed Web of Science ®Google Scholar
• Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008 Mar 1;111(5):2505–2515.
   PubMed Web of Science ®Google Scholar
• Shigemizu D, Hu Z, Hung JH, et al. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol. 2012 Feb;8(2:e1002347. DOI:10.1371/journal.pcbi.1002347.
   Google Scholar
• Ung MH, Sun CH, Weng CW, et al. Integrated Drug Expression Analysis for leukemia: an integrated in silico and in vivo approach to drug discovery. Pharmacogenomics J. 2016 Mar 15; DOI:10.1038/tpj.2016.18
   PubMed Web of Science ®Google Scholar
• Ung MH, Varn FS, Cheng C, et al. Expression analysis-integration of gene expression and clinical data for the identification of therapeutic candidates. CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):415–425. DOI:10.1002/psp4.51.
   PubMedGoogle Scholar
• Barabási AL, Oltvai ZN. Network biology: understanding the cell’s functional organization. Nat Rev Genet. 2004 Feb;5(2):101–113. DOI:10.1038/nrg1272.
   PubMed Web of Science ®Google Scholar
• Zhu X, Gerstein M, Snyder M. Getting connected: analysis and principles of biological networks. Genes Dev. 2007 May 1;21(9):1010–1024.
   PubMed Web of Science ®Google Scholar
• Mitra K, Carvunis AR, Ramesh SK, et al. Integrative approaches for finding modular structure in biological networks. Nat Rev Genet. 2013 Oct;14(10):719–732. DOI:10.1038/nrg3552.
   PubMed Web of Science ®Google Scholar
• Penrod NM, Cowper-Sal-lari R, Moore JH. Systems genetics for drug target discovery. Trends Pharmacol Sci. 2011 Oct;32(10):623–630. DOI:10.1016/j.tips.2011.07.002.
   PubMed Web of Science ®Google Scholar
• Hewett M, Oliver DE, Rubin DL, et al. PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res. 2002 Jan 1;30(1):163–165.
   PubMed Web of Science ®Google Scholar
• Griffith M, Griffith OL, Coffman AC, et al. DGIdb: mining the druggable genome. Nat Methods. 2013 Dec;10(12):1209–1210. DOI:10.1038/nmeth.2689.
   PubMed Web of Science ®Google Scholar
• Knight JA, Skol AD, Shinde A, et al. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood. 2009 May 28;113(22):5575–5582.
   PubMed Web of Science ®Google Scholar
• Kim DH, Lee ST, Won HH, et al. A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia. Blood. 2011 Jun 23;117(25):6906–6911.
   PubMed Web of Science ®Google Scholar
• Perez-Andreu V, Roberts KG, Xu H, et al. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. 2015 Jan 22;125(4):680–686.
   PubMed Web of Science ®Google Scholar
• Liu C, Yang W, Devidas M, et al. Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia. J Clin Oncol. 2016 Jun 20;34(18):2133–2140.
   PubMed Web of Science ®Google Scholar
• Speedy HE, Di Bernardo MC, Sava GP, et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2014 Jan;46(1):56–60. DOI:10.1038/ng.2843.
   PubMed Web of Science ®Google Scholar
• Berndt SI, Skibola CF, Joseph V, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet. 2013 Aug;45(8):868–876. DOI:10.1038/ng.2652.
   PubMed Web of Science ®Google Scholar
• Cao C, Moult J. GWAS and drug targets. BMC Genomics. 2014;15(Suppl 4):S5. DOI:10.1186/1471-2164-15-S4-S5.
   Google Scholar
• Paulsson K, Lilljebjörn H, Biloglav A, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet. 2015 Jun;47(6):672–676. DOI:10.1038/ng.3301.
   PubMed Web of Science ®Google Scholar
• Quesada V, Ramsay AJ, Rodríguez D, et al. The genomic landscape of chronic lymphocytic leukemia: clinical implications. BMC Med. 2013;11:124. DOI:10.1186/1741-7015-11-124.
   PubMed Web of Science ®Google Scholar
• Mullighan CG. Genome sequencing of lymphoid malignancies. Blood. 2013 Dec 5;122(24):3899–3907.
   PubMed Web of Science ®Google Scholar
• Cheng F, Zhao J, Fooksa M, et al. A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. J Am Med Inform Assoc. 2016 Mar 28;23:681–691. DOI:10.1093/jamia/ocw007.
   PubMed Web of Science ®Google Scholar
• Ung M, Liu CC, Cheng C. Integrative analysis of cancer genes in a functional interactome. Sci Rep. 2016;6:29228. DOI:10.1038/srep29228.
   PubMed Web of Science ®Google Scholar
• Menche J, Sharma A, Kitsak M, et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015 Feb 20;347(6224):1257601.
   PubMed Web of Science ®Google Scholar
• Rossin EJ, Lage K, Raychaudhuri S, et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet. 2011;7(1):e1001273. DOI:10.1371/journal.pgen.1002138.
   Google Scholar
• Leiserson MD, Blokh D, Sharan R, et al. Simultaneous identification of multiple driver pathways in cancer. PLoS Comput Biol. 2013;9(5):e1003054. DOI:10.1371/journal.pcbi.1003054.
   Web of Science ®Google Scholar
• Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013 Oct 17;502(7471):333–339.
   PubMed Web of Science ®Google Scholar
• Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1A):A68–A77. DOI:10.5114/wo.2014.47136.
   PubMedGoogle Scholar